stockrowRegencell Bioscience Holdings Limited (RGC) vs Indivior Pharmaceuticals Inc. (SUPN)
- Regencell Bioscience Holdings Limited RGC 5.32 +0.95%
- Indivior Pharmaceuticals Inc. SUPN 26.00 −2.77%
Regencell Bioscience Holdings Limited and Indivior Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Indivior Pharmaceuticals Inc. is the larger, with a market value of $5.6B against $2.6B — 2.1× the size. Regencell Bioscience Holdings Limited has negative trailing earnings, so its P/E is not meaningful; Indivior Pharmaceuticals Inc. trades at 7.0×. Indivior Pharmaceuticals Inc. has the higher net margin (32.9% vs 0.00%) and the higher return on invested capital (283.0% vs 0.00%). Across the 12 metrics below, Indivior Pharmaceuticals Inc. leads on 9 and Regencell Bioscience Holdings Limited on 3.
Valuation
Profitability
| Metric | RGC | SUPN | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | — | 84.85% | 53.51% |
| Operating margin | — | 40.57% | 0.00% |
| Net margin | 0.00% | 32.85% | (2.31%) |
| Free cash flow margin | 0.00% | 2.26% | 0.00% |
| Return on equity | 0.00% | (337.83%) | (0.80%) |
| Return on assets | 0.00% | 32.82% | (1.67%) |
| Return on invested capital | 0.00% | 283.03% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack